StemCells Inc. (NASDAQ:STEM) had its price objective reduced by S&P Equity Research from $1.57 to $1.31 in a report released on Wednesday morning.

Separately, Maxim Group cut StemCells from a buy rating to a hold rating in a report on Tuesday, May 31st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $13.72.

Shares of StemCells (NASDAQ:STEM) opened at 1.40 on Wednesday. The firm’s market capitalization is $16.81 million. The stock has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.81. StemCells has a 52 week low of $0.33 and a 52 week high of $7.56.

About StemCells

StemCells, Inc (StemCells) is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. Its lead product development program is its central nervous system (CNS) program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.

5 Day Chart for NASDAQ:STEM

Receive News & Ratings for StemCells Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemCells Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.